Pharming (PHAR) Net Income Growth (3y) (2023 - 2026)

Pharming (PHAR) Net Income Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (3y) (Qtr)
1 Oculis Holding AG 67,042.03 Bn 67,041.74 Bn - 9.16%
2 Nanobiotix 1,908.00 Bn 1,907.94 Bn - -
3 Akari Therapeutics 959.56 Bn 959.56 Bn - -
4 BeOne Medicines 471.84 Bn 467.05 Bn 1.35 Bn 38.43%
5 Vertex Pharmaceuticals 122.13 Bn 114.88 Bn 2.59 Bn 13.80%
6 Regeneron Pharmaceuticals 70.01 Bn 61.26 Bn 3.31 Bn -3.84%
7 Belite Bio 62.34 Bn 62.34 Bn - -
8 Argenx Se 55.93 Bn 50.74 Bn 1.41 Bn 79.26%
9 Alnylam Pharmaceuticals 37.49 Bn 34.48 Bn 959.66 Mn 47.10%
10 Pharming 8.96 Bn 8.91 Bn 65.80 Mn 37.38%

Historic Data

Download Data
DateValue
Mar 31, 2026 37.38%
Dec 31, 2025 -35.21%
Sep 30, 2025 -98.76%
Jun 30, 2025 -36.11%
Mar 31, 2025 -4.86%
Dec 31, 2024 -32.74%
Sep 30, 2024 27.75%
Jun 30, 2024 -56.55%
Mar 31, 2024 -33.77%
Dec 31, 2023 -11.47%
Sep 30, 2023 28.18%